Alnylam Pharmaceuticals (ALNY) Research & Development (2009 - 2026)

Alnylam Pharmaceuticals' Research & Development history runs 18 years deep, the most recent figure standing at $364.9 million for Q1 2026.

• Quarterly Research & Development rose 37.62% year-over-year to $364.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.4 billion (up 25.58% YoY) and the FY2025 annual result came in at $1.3 billion, up 17.19% from the prior year.
• Research & Development was $364.9 million for Q1 2026 at Alnylam Pharmaceuticals, down from $372.2 million in the prior quarter.
• Across five years, Research & Development topped out at $372.2 million in Q4 2025 and bottomed at $169.9 million in Q1 2022.
• A 5-year average of $276.4 million and a median of $265.1 million in 2025 frame the typical range for Research & Development.
• Annual changes were most pronounced in 2022 — Research & Development dropped 8.61% — and 2026, when it surged 37.62%.
• Alnylam Pharmaceuticals' Research & Development stood at $262.0 million in 2022, then climbed by 3.86% to $272.1 million in 2023, then increased by 10.3% to $300.2 million in 2024, then increased by 24.0% to $372.2 million in 2025, then dropped by 1.98% to $364.9 million in 2026.
• Business Quant data shows ALNY's Research & Development at $364.9 million in Q1 2026, $372.2 million in Q4 2025, and $358.8 million in Q3 2025.